Molecule
Berdazimer is a prescription medicine indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. It is available as kits. MedsAcross supplies Berdazimer for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZELSUVMI™ is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. ZELSUVMI™ is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.
Source: US FDA prescribing information
ZELSUVMI is a nitric oxide releasing agent. The mechanism of action for the treatment of molluscum contagiosum is unknown.
Source: US FDA prescribing information
Dispense equal amounts from Tube A and Tube B per the dosing guide. Mix together and immediately apply a thin layer of ZELSUVMI. Apply once daily to each MC lesion for up to 12 weeks. For topical use only and not for ophthalmic, oral, or intravaginal use.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Application Site Reactions: Application site reactions, including allergic contact dermatitis, occurred. Discontinue ZELSUVMI and initiate appropriate therapy.
Source: US FDA prescribing information
The most commonly reported adverse reactions (≥1%) are application site reactions, including pain (such as burning or stinging sensations, 18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%).
Source: US FDA prescribing information
Prior to Dispensing: Store ZELSUVMI in a refrigerator between 2°C and 8°C (36°F and 46°F) until dispensed to the patient. After Dispensing: Store ZELSUVMI at room temperature, between 20°C to 25°C (68°F and 77°F) in a dry location. Do not freeze. Discard 60 days after removal from refrigeration.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Berdazimer, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zelsuvmi kit Cold chain | Lnhc | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 5 January 2024 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Berdazimer and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Berdazimer, including Zelsuvmi.
Yes. The US FDA first approved Berdazimer on 5 January 2024, according to Drugs@FDA.
At least one listed presentation of Berdazimer must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.